Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics
暂无分享,去创建一个
A. Letai | I. Harris | E. Carrilho | D. Scadden | J. Brugge | J. Spetz | K. Sarosiek | P. Bhola | N. van Gastel | Kelley E. McQueeney | S. Parvin | J. Endress | G. Fell | Jason J. Zoeller | Veerle W. Daniels | D. S. Potter | Rajat M. Gupta | Binyam Yilma | Vinícius G. Ferreira | D. Potter
[1] A. Carnero,et al. NAD+ metabolism, stemness, the immune response, and cancer , 2021, Signal Transduction and Targeted Therapy.
[2] Jefte M. Drijvers,et al. Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells , 2020, Cancer Immunology Research.
[3] A. Letai,et al. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer , 2020, Breast cancer research : BCR.
[4] Xu Luo,et al. Faculty Opinions recommendation of BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[5] A. Letai,et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors , 2020, Science Signaling.
[6] S. Benkovic,et al. Metabolomics and mass spectrometry imaging reveal channeled de novo purine synthesis in cells , 2020, Science.
[7] Damien Y. Duveau,et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening , 2019, Science Translational Medicine.
[8] Claire O'Donovan,et al. MetaboLights: a resource evolving in response to the needs of its scientific community , 2019, Nucleic Acids Res..
[9] A. Letai,et al. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics , 2019, Cell Death & Differentiation.
[10] John G Doench,et al. Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. , 2019, Cell metabolism.
[11] V. Bafna,et al. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling , 2019, Nature.
[12] B. Daignan-Fornier,et al. Dual control of NAD+ synthesis by purine metabolites in yeast , 2019, eLife.
[13] Keisuke Hikosaka,et al. NAD Metabolism in Cancer Therapeutics , 2018, Front. Oncol..
[14] A. Strasser,et al. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. , 2018, Cancer cell.
[15] A. Strasser,et al. Humanized Mcl-1 mice enable accurate pre-clinical evaluation of MCL-1 inhibitors destined for clinical use , 2018, bioRxiv.
[16] Jing Yang,et al. Expression of long non-coding RNA and mRNA in the hippocampus of mice with type 2 diabetes , 2018, Molecular medicine reports.
[17] Lorin Crawford,et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity , 2018, Nature Communications.
[18] S. Imai,et al. Faculty of 1000 evaluation for NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. , 2018 .
[19] D. Xing,et al. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer , 2018, Cell Death & Disease.
[20] David S. Wishart,et al. HMDB 4.0: the human metabolome database for 2018 , 2017, Nucleic Acids Res..
[21] J. Montero,et al. Why do BCL-2 inhibitors work and where should we use them in the clinic? , 2017, Cell Death and Differentiation.
[22] J. Asara,et al. The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. , 2017, Cell reports.
[23] K. Glaser,et al. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation. , 2017, Biochemical and biophysical research communications.
[24] J. Visvader,et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer , 2017, Science Translational Medicine.
[25] Xin Gao,et al. Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase , 2017, Cell.
[26] H. Busch,et al. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells , 2017, Oncotarget.
[27] S. Benkovic,et al. A New View into the Regulation of Purine Metabolism: The Purinosome. , 2017, Trends in biochemical sciences.
[28] F. Sotgia,et al. Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.
[29] M. V. Vander Heiden,et al. Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. , 2016, Cell metabolism.
[30] A. Letai,et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.
[31] A. Letai,et al. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry , 2016, Biological chemistry.
[32] C. Klemke,et al. Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. , 2016, JAMA dermatology.
[33] A. Letai,et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. , 2016, Blood.
[34] G. Gordon,et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.
[35] A. Letai,et al. Mitochondria-Judges and Executioners of Cell Death Sentences. , 2016, Molecular cell.
[36] Birgit Kasch,et al. Next Generation , 2005, Im OP.
[37] Xiao-Nan Li,et al. Targeting metabolism in breast cancer: How far we can go? , 2016, World journal of clinical oncology.
[38] J. Waring,et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study , 2015, Cancer Chemotherapy and Pharmacology.
[39] W. Kiess,et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism , 2015, Nature Reviews Endocrinology.
[40] J. Auwerx,et al. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. , 2015, Cell metabolism.
[41] A. Nikiforov,et al. The human NAD metabolome: Functions, metabolism and compartmentalization , 2015, Critical reviews in biochemistry and molecular biology.
[42] J. Chi,et al. Alternative Fuels for Cancer Cells , 2015, Cancer journal.
[43] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[44] E. Chini,et al. Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors , 2013, Clinical Cancer Research.
[45] A. Letai,et al. BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.
[46] D. Vitkup,et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.
[47] M. Tan,et al. Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.
[48] A. Letai,et al. Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.
[49] M. Ziegler,et al. The NAD metabolome — a key determinant of cancer cell biology , 2012, Nature Reviews Cancer.
[50] A. Ashworth,et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells , 2012, EMBO molecular medicine.
[51] A. Letai,et al. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.
[52] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[53] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[54] C. Rudin,et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] R. Larsson,et al. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data , 2010, Cancer Chemotherapy and Pharmacology.
[56] A. Ballestrero,et al. Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE , 2009, PloS one.
[57] S. Adams,et al. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[58] A. Strasser,et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics , 2009, Nature Reviews Cancer.
[59] A. Letai,et al. Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.
[60] S. Armstrong,et al. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. , 2008, Blood.
[61] A. Letai,et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.
[62] Ying Zhang,et al. HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..
[63] S. Armstrong,et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.
[64] Michael P. Lisanti,et al. Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.
[65] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[66] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[67] C. Williamson,et al. Therapeutic perspective. , 1951, California medicine.